Skip to content

Prospective and single center clinical study of the effect of hemoglobin level on the prognosis of patients with acute ST segment elevation myocardial infarction after PCI

Prospective and single center clinical study of the effect of hemoglobin level on the prognosis of patients with acute ST segment elevation myocardial infarction after PCI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17011542
Enrollment
Unknown
Registered
2017-06-01
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Low hemoglobin level group:Consecutive patients admitted to the hospital from June 2013 to April 2016, who were clinically diagnosed with acute ST elevation myocardial infarction, were treated with pa
Mid hemoglobin level group:Consecutive patients admitted to the hospital from June 2013 to April 2016, who were clinically diagnosed with acute ST elevation myocardial infarction, were treated with pa
High hemoglobin level group:Consecutive patients admitted to the hospital from June 2013 to April 2016, who were clinically diagnosed with acute ST elevation myocardial infarction, were treated with p

Sponsors

Zhongda Hospital of Southeast University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Consecutive patients admitted to the hospital from June 2013 to April 2016, who were clinically diagnosed with acute ST elevation myocardial infarction, were treated with parallel percutaneous coronary intervention.

Exclusion criteria

Exclusion criteria: The recent (3 months) in major surgery, trauma and bleeding history; contraindications to anticoagulation and antiplatelet therapy; hemorrhagic cerebral vascular accident or within half a year have ischemic cerebrovascular accident; presence of hemorrhagic disease or thrombocytopenia; aspirin and contrast agent allergy; liver and kidney function damage; malignant tumor; clinical data coronary angiography or incomplete data.

Design outcomes

Primary

MeasureTime frame
hemoglobin;Major Adverse Cardio Cerebrovascular Event;

Countries

China

Contacts

Public ContactChengchun Tang

Department of Cardiology, Zhongda Hospital of Southeast University Medical School

tangchengchun@medmail.com.cn+86 13914705570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026